Drug intelligence / Profile preview

Suke Ganmao

Development stage
Unknown
Lead developer
Dalian Aosen Pharmaceutical
Modality
Small Molecules
Administration
Oral
01

Overview

Suke Ganmao is an oral fixed-dose combination medication developed and manufactured by Dalian Aosen Pharmaceutical (and its subsidiary Dalian Mingsen Pharmaceutical) for the symptomatic relief of the common cold and influenza. The formulation typically consists of paracetamol (acetaminophen), amantadine hydrochloride, chlorpheniramine maleate, caffeine, and artificial bezoar. Paracetamol serves as an analgesic and antipyretic by inhibiting prostaglandin synthesis, while amantadine hydrochloride provides antiviral activity against influenza A viruses. Chlorpheniramine maleate acts as an H1-antihistamine to reduce nasal congestion and sneezing, and caffeine is included to counteract the sedative effects of the antihistamine and enhance the analgesic properties of paracetamol. Artificial bezoar is a traditional component used for its antipyretic and sedative effects. It is approved in China as an over-the-counter (OTC) treatment for respiratory symptoms including fever, headache, and sore throat.

Brand names
Suke GanmaoSuke Ganmao capsule
Other names
Compound Paracetamol and Amantadine Hydrochloride Capsule速克感冒胶囊复方氨酚烷胺胶囊
02

Targets

PGHS-1 (Prostaglandin G/H Synthase 1)HRH1 (Histamine H1 Receptor)ADORA1 (Adenosine receptor A1 subtype)ADORA2A (Adenosine A₂A Receptor)CHRM2 (M2)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on Suke Ganmao.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Suke Ganmao.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call